Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Hematologic Neoplasms 2Graft vs Host Disease 2Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4Azacitidine 3venetoclax 2fludarabine phosphate 2fludarabine 2ON 01910 2Mycophenolic Acid 2Melphalan 2Filgrastim 2Cyclosporine 2Busulfan 2lonafarnib 1itacitinib 1ilorasertib 1exatecan 1darinaparsin 1cedazuridine 1Whole-Body Irradiation 1Transplantation 1Teriparatide 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Parathyroid Hormone 1Methotrexate 1Mesna 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Glycopeptides 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia, Refractory, with Excess of Blasts × Calcineurin Inhibitors × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡